Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;13(12):3831-3834.
doi: 10.21037/tlcr-24-861. Epub 2024 Dec 24.

Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?

Fabian Acker  1 , Martin Sebastian  1
Affiliations
Editorial

Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?

Fabian Acker et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor (EGFR); circulating tumor DNA (ctDNA); de-escalation; liquid biopsy (LB); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-861/coif). F.A. has received consulting fees from IQVIA, Novartis, and NovoCure, honoraria for presentations from AstraZeneca and Amgen, and support for attending meetings from Daiichi-Sankyo, AstraZeneca, and Amgen. M.S. has received an institutional research grant from AstraZeneca, honoraria for presentations from Novartis, BMS, Boehringer-Ingelheim, Pfizer, Astra-Zeneca, Takeda, Pierre-Fabre, Gilead, Daiichi-Sankyo, and Sanofi, and support for attending meetings from Takeda and Pfizer; and he has participated in data safety monitoring boards for Roche, Boehringer-Ingelheim, AstraZeneca, Sanofi, GSK, and Merck. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Dong S, Wang Z, Zhang JT, et al. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol 2024;10:932-40. 10.1001/jamaoncol.2024.1779 - DOI - PMC - PubMed
    1. Zhang JT, Liu SY, Gao W, et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov 2022;12:1690-701. 10.1158/2159-8290.CD-21-1486 - DOI - PMC - PubMed
    1. Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open 2021;6:100271. 10.1016/j.esmoop.2021.100271 - DOI - PMC - PubMed
    1. Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med 2024;391:1486-98. 10.1056/NEJMoa2403614 - DOI - PubMed
    1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-84. 10.1038/s41375-020-0776-2 - DOI - PMC - PubMed